Make a lasting impression on chronic transfusional iron overload

EXJADE^® (deferasirox) film-coated tablets provides efficacy and safety in a convenient once-daily oral tablet

Simplified administration
Proven Efficacy
Improved Adherence

Indications

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 mL/kg/month of packed red blood cells) in patients with beta thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:

In pediatric patients with beta thalassemia major with iron overload due to frequent blood transfusions (≥7 mL/kg/month of packed red blood cells) aged 2 to 5 years
In adult and pediatric patients with beta thalassemia major with iron overload due to infrequent blood transfusions (<7 mL/kg/month of packed red blood cells) aged 2 years and older
In adult and pediatric patients with other anemias aged 2 years and older

EXJADE is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with nontransfusion-dependent thalassemia syndromes aged 10 years and older.

Reference

Please note: In some countries, EXJADE film-coated tablets is available as JADENU^® (deferasirox) tablets.

Disclaimer: This is an international website for EXJADE® (deferasirox) film-coated tablets and is intended for Healthcare Professionals outside the United States. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is based on the EU Summary of Product Characteristics, not your country-specific label, and may contain information that is outside the approved indications in the country in which you are located. Always primarily consider information from the label approved in your country.